DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the NATCO PHARMA LTD. (NATCOPHARM) share price today?

NATCO PHARMA LTD. (NATCOPHARM) is trading at ₹945 on the NSE, down 2.19% on the day. Source: DocStoX.

What is the PE ratio of NATCO PHARMA LTD.?

NATCO PHARMA LTD. has a price-to-earnings (PE) ratio of 11.9 in the Healthcare sector.

What is the market capitalisation of NATCO PHARMA LTD.?

NATCO PHARMA LTD. has a market capitalisation of approximately ₹16,932 crore.

NATCO PHARMA LTD.

NATCOPHARM·NSE·Healthcare

₹945.00▼ -21.20 (-2.19%)

Healthcare · Pharmaceuticals

Debt-free and consistently profitable

NIFTY 500NIFTY SMALLCAP 250

Day₹940.10

₹968.50

52W₹789

₹122736%

Open

₹968.50

High

₹968.50

Low

₹940.10

Prev Close

₹966.20

Volume

3.38L

VWAP

₹949.40

Snapshot

Key fundamentals

Market Cap

₹16,932 Cr

P/E Ratio

11.93Cheap

P/B Ratio

1.81

EPS

₹79.20

Book Value

₹515.00

ROE

16.90%Strong

ROCE

17.00%Decent

Dividend Yield

0.52%

Debt / Equity

0.08Low

Face Value

₹2.00

52W High

₹1226.80

52W Low

₹789.00

Sector

Healthcare

Industry

Pharmaceuticals

Expensive

Narrow moatHigh uncertainty

Fair value estimate

₹717

▼ 24.1%downside

Trading at ₹945 — 24% above our estimate

BearFair valueBull

₹609₹717₹958

/100

Business quality — Solid

Growth 79Profitability 80Efficiency 23Valuation 96

Plain English

Our view

Debt-free and consistently profitable
Virtually debt-free balance sheet
Fundamental red flags (Piotroski 1/9)

Strengths

Virtually debt-free balance sheet
Profit growing 26% a year
Reasonably priced at 12× earnings

Risks

Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

17% ROE fading to 12% over ~10 yrs, on ₹515 book

₹650

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹958

Analyst target

No analyst coverage

—

Blended fair value₹717

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Profit growing 26% a year
Reasonably priced at 12× earnings

Bear case

Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

11.9Cheap

Below 15× is value territory; above 35× prices in strong growth

ROE

16.9%Strong

Above 15% is considered healthy for Indian equities

ROCE

17.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.08Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹16,932 Cr

P/B

1.81

EPS

₹79.20

Div Yield

0.52%

What changed

Recent changes

Foreign investors+2.2% stake last quarter
Promoters-0.06% stake last quarter

What matters

News impact

Overview

Valuation

Attractive

P/E 11.9×

Growth

Steady

+15% rev CAGR

Profitability

Healthy

16.9% ROE

Financial health

Rock solid

D/E 0.08

Momentum

N/A

No technicals

Today

Trading activity

Delivery %52.6%

Turnover₹3211.90L Cr

Trades22,005

VWAP₹949.40

Face value₹2.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+14.6%

+14.7%

10Y

+14.6%

Profit

+25.6%

+26.3%

10Y

+24.7%

EPS

+26.4%

+26.8%

10Y

+24.3%

Profile

Pros

Company is almost debt free.
Company has delivered good profit growth of 27.7% CAGR over last 5 years

Watch-outs

Cons

Tax rate seems low

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Promoters trimmed their stake by 0.06 pts; foreign investors bought 2.21 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

49%

Promoter

Promoters

49.4%-0.06

Public

23.3%-2.04

FII / FPI

17.4%+2.21

DII

5.5%+0.07

Others

4.4%

Total shareholders

4,10,970-13,197 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter49.42%

FII17.37%

DII5.46%

Public23.34%

Others4.41%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

NATCO PHARMA LTD. valuation & research

Deep-dive tools with DocStoX's fair-value estimate, ratios and peers.

Fair Value Intrinsic Value DCF Valuation Financial Ratios Peers

NATCO PHARMA LTD. peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

SUN PHARMACEUTICAL IND L DIVI S LABORATORIES LTD TORRENT PHARMACEUTICALS L APOLLO HOSPITALS ENTER. L ZYDUS LIFESCIENCES LTD CIPLA LTD LUPIN LIMITED MAX HEALTHCARE INS LTD MANKIND PHARMA LIMITED DR. REDDY S LABORATORIES AUROBINDO PHARMA LTD LAURUS LABS LIMITED

Compare NATCO PHARMA LTD. with peers

NATCO PHARMA LTD. vs SUN PHARMACEUTICAL IND L NATCO PHARMA LTD. vs DIVI S LABORATORIES LTD NATCO PHARMA LTD. vs TORRENT PHARMACEUTICALS L NATCO PHARMA LTD. vs APOLLO HOSPITALS ENTER. L NATCO PHARMA LTD. vs ZYDUS LIFESCIENCES LTD NATCO PHARMA LTD. vs CIPLA LTD

NATCO PHARMA LTD.

Key fundamentals

Key statistics

Recent changes

News impact

Overview

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership breakdown

Ownership over time

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Frequently asked questions

NATCO PHARMA LTD. valuation & research

NATCO PHARMA LTD. peers in Healthcare

Compare NATCO PHARMA LTD. with peers

Key statistics

Recent changes

News impact

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Ownership breakdown

Ownership over time

Frequently asked questions